A 59-year-old woman with hypertension is reviewed in clinic. She is currently taking amlodipine 10 mg daily. Her blood pressure today is 148/92 mmHg. Home blood pressure monitoring over the past week shows an average of 146/90 mmHg. She has no history of diabetes, and her potassium is 4.2 mmol/L and eGFR is 68 mL/min/1.73m². She is of White British ethnicity. What is the most appropriate next step in her antihypertensive management?
Q72
A 42-year-old man with a family history of premature coronary artery disease attends for a health check. His blood pressure is 138/84 mmHg, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L. He is a non-smoker with no diabetes. His 10-year cardiovascular risk score using QRISK3 is calculated. Which of the following interventions should be offered for primary prevention according to NICE guidelines?
Q73
A 75-year-old man is admitted with breathlessness. Clinical examination reveals elevated jugular venous pressure, bilateral basal crackles, and peripheral oedema. Echocardiography demonstrates severe mitral regurgitation with a flail posterior mitral valve leaflet and dilated left atrium (52 mm). LVEF is 64% and LV end-systolic dimension is 42 mm. He is in sinus rhythm. He has well-controlled hypertension and his functional status was excellent prior to this admission (independent, walks 2 miles daily). What is the mechanism of mitral regurgitation?
Q74
A 68-year-old woman with chronic kidney disease stage 4 (eGFR 22 mL/min/1.73m²) is diagnosed with heart failure. Echocardiography shows LVEF 34% with global hypokinesis. She is commenced on bisoprolol 1.25 mg once daily which is uptitrated to 5 mg once daily. An ACE inhibitor is considered. Baseline blood tests show: potassium 5.1 mmol/L, creatinine 246 μmol/L. What is the most appropriate approach to ACE inhibitor initiation?
Q75
A 63-year-old man attends for cardiovascular risk assessment. He is a current smoker with no other cardiovascular risk factors. His blood pressure is 132/78 mmHg, total cholesterol is 6.2 mmol/L, HDL 1.1 mmol/L, and non-HDL cholesterol is 5.1 mmol/L. His QRISK3 score is calculated as 11.4%. What is the most appropriate management regarding his cardiovascular risk?
Q76
A 51-year-old woman presents to the Emergency Department with 2 hours of central chest pain. She has a history of systemic lupus erythematosus (SLE) treated with hydroxychloroquine and intermittent prednisolone. ECG shows ST-segment elevation of 3 mm in leads V2-V4. High-sensitivity troponin I is 2,840 ng/L (normal <16 ng/L). She undergoes emergency angiography which shows normal coronary arteries with no evidence of atherosclerosis. What is the most likely diagnosis?
Q77
A 70-year-old woman with heart failure is reviewed in clinic. She has heart failure with preserved ejection fraction (HFpEF) with LVEF 56% on recent echocardiography. She remains breathless on minimal exertion (NYHA class III) despite maximal diuretic therapy. She has a history of type 2 diabetes, hypertension, and obesity (BMI 34 kg/m²). Her blood pressure is 142/88 mmHg and heart rate 78 bpm in sinus rhythm. Which medication has the strongest evidence for reducing heart failure hospitalisations in this patient?
Q78
A 56-year-old man with newly diagnosed paroxysmal atrial fibrillation is being considered for rhythm control. He has episodes lasting 2-6 hours occurring 2-3 times per week. His echocardiogram shows normal left ventricular function and no structural heart disease. He has no history of ischaemic heart disease. His blood pressure is 128/76 mmHg and resting heart rate is 68 bpm in sinus rhythm. Which anti-arrhythmic medication is most appropriate for rhythm control?
Q79
A 77-year-old man presents with progressive exertional dyspnoea over 6 months. Examination reveals a slow-rising pulse, narrow pulse pressure, and an ejection systolic murmur radiating to the carotids. Echocardiography confirms severe aortic stenosis with a valve area of 0.7 cm², mean pressure gradient of 48 mmHg, and preserved LVEF of 58%. He has significant frailty with reduced mobility and multiple comorbidities. Coronary angiography shows non-obstructive coronary disease. What is the most appropriate definitive management?
Q80
A 44-year-old woman who emigrated from India 15 years ago presents with progressive dyspnoea and orthopnoea. She has an early diastolic murmur best heard at the left sternal edge when sitting forward. Echocardiography shows severe aortic regurgitation with a dilated left ventricle. LVEF is 48%, left ventricular end-systolic diameter is 52 mm. She is asymptomatic at rest but becomes breathless after climbing one flight of stairs. What is the most appropriate management?
Cardiology UK Medical PG Practice Questions and MCQs
Question 71: A 59-year-old woman with hypertension is reviewed in clinic. She is currently taking amlodipine 10 mg daily. Her blood pressure today is 148/92 mmHg. Home blood pressure monitoring over the past week shows an average of 146/90 mmHg. She has no history of diabetes, and her potassium is 4.2 mmol/L and eGFR is 68 mL/min/1.73m². She is of White British ethnicity. What is the most appropriate next step in her antihypertensive management?
A. Add ramipril to her current therapy (Correct Answer)
B. Replace amlodipine with ramipril
C. Add indapamide to her current therapy
D. Add doxazosin to her current therapy
E. Increase amlodipine to 15 mg daily
Explanation: ***Add ramipril to her current therapy***- According to **NICE guidelines (NG136)**, for a patient aged over 55 or of White British ethnicity without diabetes, initial therapy is a **Calcium Channel Blocker (CCB)**. As her blood pressure remains uncontrolled despite optimal CCB monotherapy, the next step (Step 2) is to **add an ACE inhibitor** or ARB.- Her current blood pressure of 148/92 mmHg (clinic) and 146/90 mmHg (home) indicates inadequate control, warranting the addition of a second-line agent like **ramipril** to achieve the target blood pressure of less than **140/90 mmHg** (clinic) or **135/85 mmHg** (home).*Replace amlodipine with ramipril*- Hypertension treatment usually follows a **stepwise approach**, adding new agents rather than replacing existing ones, especially when the current medication is providing some benefit.- Replacing amlodipine would mean losing the **partial blood pressure control** achieved by the CCB and restarting therapy, which is less effective than combination therapy in uncontrolled hypertension.*Add indapamide to her current therapy*- **Thiazide-like diuretics** such as indapamide are recommended at **Step 3** of the NICE hypertension algorithm.- Step 3 therapy involves a **combination** of an ACE inhibitor/ARB, a CCB, and a thiazide-like diuretic, which is not appropriate at this current stage (Step 2).*Add doxazosin to her current therapy*- **Alpha-blockers** like doxazosin are considered in **Step 4** for the management of **resistant hypertension**.- Resistant hypertension is defined as uncontrolled blood pressure despite treatment with optimal doses of an **ACE inhibitor/ARB, CCB, and thiazide-like diuretic**, which is not the case here.*Increase amlodipine to 15 mg daily*- The **maximum licensed daily dose** of amlodipine for the treatment of hypertension is **10 mg**.- Increasing the dose beyond 10 mg is not recommended due to limited additional therapeutic benefit and an increased risk of **dose-dependent side effects**, such as peripheral edema.
Question 72: A 42-year-old man with a family history of premature coronary artery disease attends for a health check. His blood pressure is 138/84 mmHg, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L. He is a non-smoker with no diabetes. His 10-year cardiovascular risk score using QRISK3 is calculated. Which of the following interventions should be offered for primary prevention according to NICE guidelines?
A. Atorvastatin 20 mg once daily if QRISK3 ≥10% (Correct Answer)
B. Atorvastatin 40 mg once daily if QRISK3 ≥10%
C. Atorvastatin 80 mg once daily if QRISK3 ≥10%
D. Simvastatin 40 mg once daily if QRISK3 ≥20%
E. Pravastatin 40 mg once daily if QRISK3 ≥10%
Explanation: ***Atorvastatin 20 mg once daily if QRISK3 ≥10%***- According to **NICE guidelines**, **Atorvastatin 20 mg** is the first-line medication recommended for the **primary prevention** of cardiovascular disease in adults.- Intervention is indicated when the calculated **QRISK3 score** is **10% or greater**, indicating a significant 10-year risk of developing CVD.*Atorvastatin 40 mg once daily if QRISK3 ≥10%*- A dose of **40 mg** is higher than the standard starting dose recommended for **primary prevention** in the general population.- Higher doses like this are typically considered only if the initial **20 mg dose** fails to achieve a **>40% reduction** in non-HDL cholesterol.*Atorvastatin 80 mg once daily if QRISK3 ≥10%*- **Atorvastatin 80 mg** is specifically indicated for **secondary prevention** in patients with established CVD, such as those post-myocardial infarction.- Initiating primary prevention at this dose is inappropriate due to an increased risk of **side effects** without evidence-based necessity.*Simvastatin 40 mg once daily if QRISK3 ≥20%*- **Simvastatin** is no longer the preferred first-line statin due to its shorter half-life and more frequent **drug-drug interactions** compared to atorvastatin.- The threshold for intervention has been lowered from **20% to 10%** in modern NICE guidelines to broaden the population benefiting from therapy.*Pravastatin 40 mg once daily if QRISK3 ≥10%*- **Pravastatin** is considered a lower-potency statin and is not the first-line choice for **CVD primary prevention** under current NICE clinical standards.- It is generally reserved for patients who cannot tolerate **high-intensity statins** like atorvastatin due to muscle-related side effects.
Question 73: A 75-year-old man is admitted with breathlessness. Clinical examination reveals elevated jugular venous pressure, bilateral basal crackles, and peripheral oedema. Echocardiography demonstrates severe mitral regurgitation with a flail posterior mitral valve leaflet and dilated left atrium (52 mm). LVEF is 64% and LV end-systolic dimension is 42 mm. He is in sinus rhythm. He has well-controlled hypertension and his functional status was excellent prior to this admission (independent, walks 2 miles daily). What is the mechanism of mitral regurgitation?
A. Degenerative (myxomatous) disease (Correct Answer)
B. Rheumatic heart disease
C. Functional mitral regurgitation
D. Infective endocarditis
E. Ischaemic mitral regurgitation
Explanation: ***Degenerative (myxomatous) disease***- The presence of a **flail posterior mitral valve leaflet** due to chordal rupture is the hallmark of **myxomatous degeneration**, which is the most common cause of primary mitral regurgitation in older patients.- It leads to **Carpentier Type II** dysfunction where the leaflet tip extends into the left atrium during systole, consistent with this patient's acute-on-chronic presentation and **preserved LVEF**.*Rheumatic heart disease*- Typically presents with **commissural fusion**, leaflet thickening, and restricted motion (**Carpentier Type IIIa**), rather than a flail leaflet.- Often involves a history of rheumatic fever and frequently affects the **aortic valve** concurrently, which is not described here.*Functional mitral regurgitation*- Occurs in structurally normal valves because of **left ventricular dilatation** or remodeling that prevents proper leaflet coaptation (**Carpentier Type I or IIIb**).- This is unlikely here as the patient has a **preserved LVEF (64%)** and a primary structural abnormality (flail leaflet).*Infective endocarditis*- While it can cause valve destruction and flail leaflets, it typically presents with **systemic symptoms** like fever, weight loss, and **vegetations** on echocardiography.- There is no clinical evidence of infection or leukocytosis in this patient's history to support this diagnosis.*Ischaemic mitral regurgitation*- Usually results from **papillary muscle dysfunction** or rupture following a myocardial infarction, or from **regional wall motion abnormalities**.- This patient has no history of ischaemic heart disease and maintains a **normal ejection fraction**, making an acute ischaemic event causing a flail leaflet less probable.
Question 74: A 68-year-old woman with chronic kidney disease stage 4 (eGFR 22 mL/min/1.73m²) is diagnosed with heart failure. Echocardiography shows LVEF 34% with global hypokinesis. She is commenced on bisoprolol 1.25 mg once daily which is uptitrated to 5 mg once daily. An ACE inhibitor is considered. Baseline blood tests show: potassium 5.1 mmol/L, creatinine 246 μmol/L. What is the most appropriate approach to ACE inhibitor initiation?
A. Start ramipril 1.25 mg once daily and check U&Es after 1-2 weeks (Correct Answer)
B. Avoid ACE inhibitor due to CKD stage 4
C. Start ramipril 2.5 mg once daily and check U&Es after 1 month
D. Start sacubitril-valsartan instead of ACE inhibitor
E. Wait until potassium falls below 5.0 mmol/L before starting
Explanation: ***Start ramipril 1.25 mg once daily and check U&Es after 1-2 weeks***
- In patients with **advanced CKD** (eGFR <30 mL/min/1.73m²), ACE inhibitors should be started at a **very low dose** (e.g., ramipril 1.25 mg) and uptitrated slowly to minimize risks of acute kidney injury and hyperkalemia.
- **Urea, electrolytes, and creatinine (U&Es)** must be monitored closely, typically **1 to 2 weeks** after initiation or dose changes, to ensure the creatinine rise is <30% and potassium remains <6.0 mmol/L.
*Avoid ACE inhibitor due to CKD stage 4*
- ACE inhibitors provide significant **mortality benefits** in heart failure with reduced ejection fraction (**HFrEF**) and should not be withheld based on CKD alone unless potassium is >5.5 mmol/L or there is severe renal artery stenosis.
- Chronic kidney disease is often an indication for, rather than a contraindication to, ACE inhibition due to its **renoprotective effects** on proteinuria, though close monitoring is required.
*Start ramipril 2.5 mg once daily and check U&Es after 1 month*
- A starting dose of **2.5 mg** is considered standard for many, but in the context of **CKD Stage 4**, starting at the lowest possible dose (1.25 mg) is safer to prevent precipitous drops in GFR.
- Waiting **one month** for follow-up blood tests is too long for a high-risk patient with low eGFR; early monitoring at **1-2 weeks** is the clinical standard.
*Start sacubitril-valsartan instead of ACE inhibitor*
- Current guidelines recommend stabilizing the patient on an **ACE inhibitor or ARB** first before switching to **sacubitril-valsartan** (ARNI) to ensure tolerance to RAAS inhibition.
- ARNI initiation requires a **36-hour washout period** if switching from an ACE inhibitor to avoid angioedema and is generally not used as the first-line RAAS agent in newly diagnosed HFrEF.
*Wait until potassium falls below 5.0 mmol/L before starting*
- Initiation of an ACE inhibitor is generally considered safe if the baseline **potassium is <5.5 mmol/L**; therefore, a level of 5.1 mmol/L does not require a delay in treatment.
- Delaying life-saving therapy for HFrEF to reach a specific potassium threshold under 5.0 mmol/L unnecessarily increases the patient's **cardiovascular risk**.
Question 75: A 63-year-old man attends for cardiovascular risk assessment. He is a current smoker with no other cardiovascular risk factors. His blood pressure is 132/78 mmHg, total cholesterol is 6.2 mmol/L, HDL 1.1 mmol/L, and non-HDL cholesterol is 5.1 mmol/L. His QRISK3 score is calculated as 11.4%. What is the most appropriate management regarding his cardiovascular risk?
A. Offer atorvastatin 20 mg and lifestyle advice (Correct Answer)
B. Provide lifestyle advice only and reassess in 5 years
C. Offer atorvastatin 80 mg and lifestyle advice
D. Arrange further investigations including CT calcium score
E. Provide lifestyle advice and reassess QRISK3 in 1 year
Explanation: ***Offer atorvastatin 20 mg and lifestyle advice***
- According to **NICE guidelines**, primary prevention with statins should be offered to individuals with a **QRISK3 score ≥10%**.
- The recommended first-line treatment for **primary prevention** of cardiovascular disease is **atorvastatin 20 mg** daily alongside lifestyle modifications, especially given the **elevated non-HDL cholesterol** and smoking status.
*Provide lifestyle advice only and reassess in 5 years*
- While lifestyle advice is essential, it is insufficient as the patient's **QRISK3 score (11.4%)** has already exceeded the **10% threshold** for pharmacological intervention.
- Delaying treatment for five years in a high-risk patient significantly increases the cumulative risk of a **major adverse cardiovascular event (MACE)**.
*Offer atorvastatin 80 mg and lifestyle advice*
- High-dose **atorvastatin 80 mg** is primarily indicated for **secondary prevention** in patients with established cardiovascular disease, or for very high-risk primary prevention, not typically as an initial dose for this presentation.
- Starting at such a high dose for primary prevention increases the risk of side effects like **myalgia** and **liver enzyme elevation** without clear necessity.
*Arrange further investigations including CT calcium score*
- A **CT calcium score** is generally reserved for cases where clinical risk is uncertain or when the **QRISK score** sits near the threshold and the decision to treat is unclear.
- Because this patient's score is clearly **above 10%**, the indication for treatment is already established, making further imaging unnecessary for management.
*Provide lifestyle advice and reassess QRISK3 in 1 year*
- Reassessing in one year unnecessarily delays the initiation of **statin therapy** for a patient who currently meets the diagnostic criteria for intervention.
- Management should prioritize immediate risk reduction through **smoking cessation** and lipid-lowering therapy given the current **elevated QRISK3 score** and **non-HDL cholesterol**.
Question 76: A 51-year-old woman presents to the Emergency Department with 2 hours of central chest pain. She has a history of systemic lupus erythematosus (SLE) treated with hydroxychloroquine and intermittent prednisolone. ECG shows ST-segment elevation of 3 mm in leads V2-V4. High-sensitivity troponin I is 2,840 ng/L (normal <16 ng/L). She undergoes emergency angiography which shows normal coronary arteries with no evidence of atherosclerosis. What is the most likely diagnosis?
A. Coronary vasospasm
B. Coronary artery dissection
C. Myocarditis (Correct Answer)
D. Takotsubo cardiomyopathy
E. Type 2 myocardial infarction
Explanation: ***Myocarditis***
- In patients with **Systemic Lupus Erythematosus (SLE)**, immune-mediated myocardial inflammation often mimics an acute myocardial infarction, presenting with **ST-segment elevation** and significant **troponin elevation**.
- The presence of **normal coronary arteries** on angiography in a symptomatic patient with cardiac enzyme leak and ECG changes (MINOCA) strongly points toward **myocarditis** as a common SLE-related cardiac manifestation.
*Coronary vasospasm*
- This condition involves transient narrowing of the arteries; while it can cause **ST elevation**, it typically does not result in such a massive and sustained **troponin rise** (2,840 ng/L).
- Vasospasm is usually identified during angiography through clinical observation or provocation testing with **acetylcholine**, which was not reported here.
*Coronary artery dissection*
- **Spontaneous Coronary Artery Dissection (SCAD)** is a known cause of MI in females, but it would typically show an **intimal flap** or an obstructive hematoma on **emergency angiography**.
- This patient's coronary arteries were specifically described as **normal**, which effectively rules out the structural disruption seen in dissection.
*Takotsubo cardiomyopathy*
- Often triggered by **emotional or physical stress**, this condition classically presents with **apical ballooning** and wall motion abnormalities that transcend a single vascular territory.
- While it presents with normal coronaries, it is not a direct complication of **SLE** compared to the high prevalence of inflammatory **myocarditis** in lupus patients.
*Type 2 myocardial infarction*
- This occurs due to **oxygen supply-demand mismatch** caused by conditions like severe anemia, sepsis, or tachyarrhythmias, none of which are described in this clinical vignette.
- It is characterized by a rise and fall of troponin without **primary coronary events**, but the focal ST elevation (V2-V4) is less typical than diffuse changes in a demand-related event.
Question 77: A 70-year-old woman with heart failure is reviewed in clinic. She has heart failure with preserved ejection fraction (HFpEF) with LVEF 56% on recent echocardiography. She remains breathless on minimal exertion (NYHA class III) despite maximal diuretic therapy. She has a history of type 2 diabetes, hypertension, and obesity (BMI 34 kg/m²). Her blood pressure is 142/88 mmHg and heart rate 78 bpm in sinus rhythm. Which medication has the strongest evidence for reducing heart failure hospitalisations in this patient?
A. SGLT2 inhibitor (Correct Answer)
B. Spironolactone
C. ACE inhibitor
D. Sacubitril-valsartan
E. Beta-blocker
Explanation: ***SGLT2 inhibitor***- Evidence from trials like **EMPEROR-Preserved** and **DELIVER** demonstrates that **SGLT2 inhibitors** significantly reduce the risk of **heart failure hospitalizations** in patients with HFpEF, regardless of diabetes status.- These agents are now considered foundational therapy in **ESC and ACC/AHA guidelines** for HFpEF (LVEF ≥50%), making them the strongest choice for this patient.*Spironolactone*- The **TOPCAT trial** showed a reduction in heart failure hospitalizations but failed to show a significant benefit for the primary composite endpoint of **cardiovascular mortality**.- While useful as an add-on therapy, its evidence base for HFpEF is considered weaker and more geographically inconsistent compared to SGLT2 inhibitors.*ACE inhibitor*- Large-scale trials such as **PEP-CHF** (perindopril) failed to demonstrate a significant reduction in long-term mortality or cardiovascular outcomes in HFpEF.- While indicated for managing this patient's **hypertension**, they do not carry the specific primary evidence for reducing heart failure events in the HFpEF population.*Sacubitril-valsartan*- The **PARAGON-HF trial** narrowly missed its primary endpoint, showing only a marginal benefit that was more pronounced in women and those with an **LVEF at the lower end** of the HFpEF range.- It is not currently the first-line choice for reducing hospitalizations in a patient with a confirmed **LVEF of 56%**.*Beta-blocker*- There is no high-quality clinical trial evidence to suggest that **beta-blockers** improve mortality or reduce hospitalizations in patients with HFpEF.- They are generally only recommended in this population if required for secondary indications like **atrial fibrillation** or **ischemic heart disease**.
Question 78: A 56-year-old man with newly diagnosed paroxysmal atrial fibrillation is being considered for rhythm control. He has episodes lasting 2-6 hours occurring 2-3 times per week. His echocardiogram shows normal left ventricular function and no structural heart disease. He has no history of ischaemic heart disease. His blood pressure is 128/76 mmHg and resting heart rate is 68 bpm in sinus rhythm. Which anti-arrhythmic medication is most appropriate for rhythm control?
A. Flecainide (Correct Answer)
B. Amiodarone
C. Sotalol
D. Digoxin
E. Verapamil
Explanation: ***Flecainide***
- **Flecainide** is a first-line agent for rhythm control in patients with paroxysmal atrial fibrillation who have **no structural heart disease** or ischemic heart disease.
- As a **Class Ic anti-arrhythmic**, it is highly effective at maintaining sinus rhythm but must be avoided in those with **coronary artery disease** due to the risk of pro-arrhythmia.
*Amiodarone*
- While highly effective, **Amiodarone** is generally reserved for patients with significant **structural heart disease** or when other agents have failed.
- It has a high incidence of long-term toxicities, including **pulmonary fibrosis**, **thyroid dysfunction**, and **hepatotoxicity**.
*Sotalol*
- **Sotalol** has both Class II (beta-blocking) and Class III properties but carries a significant risk of **QT interval prolongation** and Torsades de Pointes.
- It is less effective than flecainide for rhythm control and requires close monitoring of **renal function** and electrolytes.
*Digoxin*
- **Digoxin** is strictly a **rate control** agent that acts by slowing conduction through the AV node; it does not convert or maintain sinus rhythm.
- It is particularly ineffective at controlling heart rate during **exercise** or high-sympathetic states, making it unsuitable for paroxysmal AF rhythm management.
*Verapamil*
- **Verapamil** is a non-dihydropyridine calcium channel blocker used for **rate control** by increasing the refractory period of the AV node.
- It has no role in **rhythm control** (cardioversion or maintenance of sinus rhythm) in patients with atrial fibrillation.
Question 79: A 77-year-old man presents with progressive exertional dyspnoea over 6 months. Examination reveals a slow-rising pulse, narrow pulse pressure, and an ejection systolic murmur radiating to the carotids. Echocardiography confirms severe aortic stenosis with a valve area of 0.7 cm², mean pressure gradient of 48 mmHg, and preserved LVEF of 58%. He has significant frailty with reduced mobility and multiple comorbidities. Coronary angiography shows non-obstructive coronary disease. What is the most appropriate definitive management?
A. Transcatheter aortic valve implantation (TAVI) (Correct Answer)
B. Surgical aortic valve replacement
C. Medical management with diuretics
D. Balloon aortic valvuloplasty
E. Cardiac resynchronisation therapy
Explanation: ***Transcatheter aortic valve implantation (TAVI)***
- **TAVI** is the preferred treatment for patients over **75 years of age** or those with **significant frailty** and high surgical risk, as it is less invasive than open surgery.
- The patient has symptomatic **severe aortic stenosis** (mean gradient >40 mmHg, valve area <1.0 cm²), which requires definitive intervention to improve survival.
*Surgical aortic valve replacement*
- While a standard treatment for severe aortic stenosis, it is often avoided in patients with **multiple comorbidities** and **significant frailty** due to high operative risk.
- Modern guidelines increasingly favor **TAVI** over surgical replacement in elderly cohorts even when surgical risk is intermediate.
*Medical management with diuretics*
- Medical therapy does not address the underlying **mechanical obstruction** and is associated with a **50% mortality rate** at 2 years once symptoms develop.
- Diuretics may offer temporary symptomatic relief for **heart failure** symptoms but are not a definitive therapy for severe valvular disease.
*Balloon aortic valvuloplasty*
- This procedure typically provides only **temporary relief** as the valve frequently restenoses within 6 to 12 months.
- It is generally reserved as a **bridge to definitive therapy** (like TAVI) or for palliative care in patients who are hemodynamically unstable.
*Cardiac resynchronisation therapy*
- This intervention is indicated for patients with **reduced LVEF** and specific conduction abnormalities like **left bundle branch block**.
- It has no role in the primary management of **severe aortic stenosis** and would not address the patient's outflow obstruction.
Question 80: A 44-year-old woman who emigrated from India 15 years ago presents with progressive dyspnoea and orthopnoea. She has an early diastolic murmur best heard at the left sternal edge when sitting forward. Echocardiography shows severe aortic regurgitation with a dilated left ventricle. LVEF is 48%, left ventricular end-systolic diameter is 52 mm. She is asymptomatic at rest but becomes breathless after climbing one flight of stairs. What is the most appropriate management?
A. Aortic valve replacement (Correct Answer)
B. ACE inhibitor therapy and annual echocardiography
C. Diuretic therapy and symptom monitoring
D. Cardiac MRI for tissue characterisation
E. Exercise stress testing
Explanation: ***Aortic valve replacement***- This patient has **severe aortic regurgitation (AR)** and meets surgical criteria due to the presence of **symptoms** (dyspnoea and orthopnoea) and an **LVEF <50%** (48% in this case).- Even if symptoms were absent, an **LV end-systolic diameter (LVESD) >50 mm** (measured here as 52 mm) is an independent indication for surgery to prevent irreversible myocardial damage.*ACE inhibitor therapy and annual echocardiography*- While **ACE inhibitors** can manage hypertension associated with AR, they do not delay the need for surgery once **Class I surgical indications** are met.- Annual monitoring is inappropriate for this patient because she has already developed **LV dysfunction** and clinical symptoms requiring urgent intervention.*Diuretic therapy and symptom monitoring*- **Diuretics** may provide temporary symptomatic relief for pulmonary congestion but do not address the underlying **valvular mechanical defect**.- Delaying surgery for symptom monitoring in a patient with a **dilated ventricle** and low LVEF increases the risk of **permanent heart failure**.*Cardiac MRI for tissue characterisation*- **Echocardiography** has already clearly defined the severity of the AR and the resulting **ventricular secondary changes**, making MRI redundant for the primary diagnosis.- While MRI is useful if echo windows are poor, it should not delay the **definitive surgical management** required for this symptomatic patient.*Exercise stress testing*- Exercise testing is primarily used to unmask symptoms in patients who claim to be **asymptomatic** despite severe AR.- This patient is already **overtly symptomatic** (NYHA class II), so an exercise test provides no additional diagnostic value and may be unnecessarily risky.
